VirusExpress® Lentivirus Production Platform by Merck – Scalable, GMP-compliant, High-Titer Lentiviral Vector Production

Lentiviral vector production must meet demanding requirements for scalability, regulatory compliance, and fast process development, making a robust VirusExpress Lentivirus Production Platform especially valuable for gene therapy programs.

Why choose the VirusExpress Lentivirus Production Platform

• Faster development timelines: Reduces process development and scale-up time by approximately 40%.
• Accelerated therapy delivery: Helps speed your therapy to patients.
• Scalable manufacturing readiness: Supports production at clinically and commercially relevant scales with proven performance at 50 L.
• High titer output: Achieves functional titers exceeding 4 × 10⁷ TU/mL.
• Regulatory support: Provides robust quality documentation and full traceability to support regulatory filings and commercialization.
• Quality and compliance confidence: Uses GMP-banked cells that are fully characterized and adventitious agent tested, with characterization in accordance with FDA cGMP regulations.
• Flexible deployment: Can be implemented in your own facilities or through contract manufacturing capabilities.
• Development-stage licensing access: Licenses are available for research, clinical, and commercial use depending on gene therapy development needs.

What’s included in the VirusExpress Lentivirus Production Platform

• Transfection-based upstream production architecture: Lentiviral vector production is based on a transient transfection process for upstream manufacturing.
• Suspension-adapted cell line: 293T Lentiviral Production Cells are adapted to suspension culture and optimized for production of lentiviral vectors for gene therapy applications.
• Cell line selection basis: HEK293T VirusExpress® Cells were selected for higher lentivirus production using a PEI-based transient transfection method.
• Chemically defined medium: The platform includes a chemically defined medium that is animal component-free and intended to address animal origin and supply chain concerns.
• User protocol package: Comprehensive protocols cover seed train, at-scale transfection, and virus production.
• Manufacturing model: The platform can be implemented within your own facilities or used with contract manufacturing capabilities.

Technical specifications for the VirusExpress Lentivirus Production Platform

• Proven process performance: demonstrated at 50 L scale
• Functional titer: exceeding 4 × 10⁷ TU/mL
• Process development and scale-up time reduction: approximately 40%
• Characterization and regulatory references cited: FDA cGMP regulations 21 CFR 210, 211, 600, and 610

Applications and usage

• Upstream lentiviral production: Applied as a transfection-based solution specifically for upstream lentiviral production challenges.
• Lentiviral vector manufacturing for gene therapy: Used with 293T Lentiviral Production Cells optimized for production of lentiviral vectors for gene therapy applications.
• Suspension-based lentivirus production: Used for suspension-adapted lentivirus production workflows with a scalable upstream process.
• Seed train to virus production workflow: Used across the process from seed train through at-scale transfection and virus production following the provided user protocols.
• PEI-based transient transfection workflows: Compatible with PEI-based transient transfection methods for lentivirus production (PEI reagent supplied separately).
• Large-scale bioreactor scale-up: Used for scale-up from shake flask culture to large-scale bioreactor production.

Products within the VirusExpress Lentivirus Production Platform

Chemical Express, with over 23 years of expertise, is the official distributor of Merck in Thailand. Purchase VirusExpress® Lentivirus Production Platform and other related products from leading brands at Chemical Express to ensure quality, regulatory support and trusted supply for your gene therapy and bioprocessing needs.